Sign In
Buy GMAB
$23.88
+0.0300 (+0.126%)
At Close: Jun 03, 2026
This Dutch Drugmaker's Stock Is Jumping 38%. Here's Why It's Being Acquired.
07:36am, Monday, 29'th Sep 2025
Genmab will acquire Merus in an all-cash transaction worth around $8 billion.
Genmab to acquire Dutch biotech Merus in $8B deal to expand cancer pipeline
03:23am, Monday, 29'th Sep 2025
Denmark's Genmab has agreed to acquire Merus NV, a Nasdaq-listed Dutch biotechnology company, in an all-cash transaction valued at $8 billion, the companies announced on Monday. The deal marks a signi
Genmab to buy Dutch cancer drugmaker Merus for $8 billion
01:19am, Monday, 29'th Sep 2025
Denmark's Genmab has agreed to acquire Merus NV , a Nasdaq-listed Dutch biotech firm developing a head-and-neck cancer drug, for $8 billion in cash, the two companies said on Monday.
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
01:14am, Monday, 29'th Sep 2025
COPENHAGEN, Denmark & UTRECHT, Netherlands--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) and Merus N.V. (Nasdaq: MRUS) announced today that they have entered into a transaction agreement pursuant to whi
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
01:08am, Monday, 29'th Sep 2025
Company Announcement Genmab to acquire Merus for USD 97.00 per share in an all-cash transaction representing a transaction value of approximately USD 8.0 billion Proposed acquisition adds petosemtamab
Grant of Restricted Stock Units and Warrants to Employees in Genmab
07:14pm, Thursday, 25'th Sep 2025
Company Announcement COPENHAGEN, Denmark; September 26, 2025 – Genmab A/S (Nasdaq: GMAB) announced today that the Board of Directors decided to grant 14,353 restricted stock units and 9,681 warrants
Genmab A/S (GMAB) Presents at Bank of America Global Healthcare Conference 2025 Transcript
03:17am, Thursday, 25'th Sep 2025
Genmab A/S (GMAB) Bank of America Global Healthcare Conference 2025 September 23, 2025 6:35 AM EDT Company Participants Anthony Pagano - Executive VP & CFO Conference Call Participants Sachin Jain - B
Major Shareholder Announcement
09:18am, Tuesday, 23'rd Sep 2025
Company Announcement Major shareholder announcement for Genmab A/S COPENHAGEN, Denmark; September 23, 2025 – Genmab A/S (Nasdaq: GMAB) announces under reference to Section 30 of the Danish Capital M
Genmab Transitioning To A Global Oncology Powerhouse: Why I Choose To Buy
08:31am, Sunday, 14'th Sep 2025
Genmab is rated BUY due to strong royalty income, surging drug sales, and a robust late-stage oncology pipeline. GMAB's H1 2025 revenue rose 19%, driven by Darzalex royalties and rapid growth in self-
Genmab: Epkinly's Spectacular Data Is The Antidote To The Darzalex Patent Cliff
01:58pm, Friday, 12'th Sep 2025
Genmab A/S is leveraging its royalty-centric model and new ADCs like Epkinly to offset upcoming Darzalex patent expiry risks. Epkinly's strong Phase 3 data in follicular lymphoma positions GMAB for bl
Genmab: A Matter Of Time
06:15am, Friday, 12'th Sep 2025
Genmab raised the full-year revenue and operating income guidance after strong Q2 results, driven by robust royalty streams and growing net sales of Epkinly and Tivdak. Genmab's maturing and expanding
Genmab A/S (GMAB) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript
06:41pm, Tuesday, 09'th Sep 2025
Genmab A/S (GMAB) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 7:45 AM EDT Company Participants Jan van de Winkel - Co-Founder, President & CEO Anthony Pagano - Executive
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons
02:57pm, Tuesday, 09'th Sep 2025
Company Announcement COPENHAGEN, Denmark; September 9, 2025 – Genmab A/S (Nasdaq: GMAB) - In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/52
Capital Increase in Genmab as a Result of Employee Warrant Exercise
02:54pm, Tuesday, 09'th Sep 2025
Company Announcement COPENHAGEN, Denmark; September 09, 2025 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 47,532 shares as a consequence of the exercise of employee warrants. The i
Media Release COPENHAGEN, Denmark; September 3, 2025 Trial demonstrated the feasibility of treating and monitoring adult patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) i
